Bob Oebrien
CEO at O'Brien Capital, LLC
St. Louis, Missouri
Bob Oebrien, CEO at O'Brien Capital, LLC is an active investor based in St. Louis, Missouri. This profile covers what Bob Oebrien backs, at which stage, and how founders can reach out in 2026.
- Investor type
- PE
- Stages
- Series BLate Stage Venture
- Invests in
- Marketplace
- Location
- St. Louis, Missouri
- Typical check
- $5M
- Past investments
- 1
Notable investments
How to reach Bob Oebrien
Angels and operators like Bob Oebrien reply to specific, personalized notes that show real traction, not mass blasts. Build a verified list, write a note that fits their thesis, and track replies, all on Round Funded.
Connect with Bob Oebrien
About this profile
This profile is part of Round Funded, an investor database and outreach platform for founders. It covers 60,000+ active VCs, angels, family offices and accelerators with verified contacts, lets you send pitches from your own Gmail, and includes a free Data Room for your raise.
Frequently Asked Questions
What does Bob Oebrien invest in?
Bob Oebrien invests in Marketplace, typically at Series B and Late Stage Venture. Match your sector and stage, then reach out with a personalized pitch.
What stage does Bob Oebrien invest at?
Bob Oebrien typically invests at Series B and Late Stage Venture. Lead with traction that fits the stage when you reach out.
What is Bob Oebrien's typical check size?
Bob Oebrien typically writes checks around $5M. Use it as a signal for whether your raise fits their stage.
How do I contact Bob Oebrien?
Unlock Bob Oebrien's verified email on Round Funded and send a personalized pitch. We surface only deliverable contacts so your outreach lands.
What is Round Funded?
Round Funded is an investor database and outreach platform for startup founders. It lists 60,000+ active investors with verified contacts, filtered to recent investment activity, and lets founders send personalized pitches from their own Gmail, track replies, and share a free Data Room. Round+ starts at $99 per month with a 3-day trial.